巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Royalty Pharma plc

    RPRX
    44.380
    0.500
    1.14%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Royalty Pharma plc - 延遲價格・最後更新於 16/08 12:00
    最高位
    44.550
    最低位
    43.760
    開市價
    --
    前收市價
    43.880
    成交量(千)
    101.95
    成交額(百萬)
    40.80
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    19,475.72
    市盈率
    42.710
    息率
    1.64%
    差價
    --
    52週高低
    44.750 - 34.860
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Royalty Pharma plc
    證券代碼
    RPRX.US
    所屬板塊
    Biotechnology
    公司業務
    Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
    發行量
    434705598
    公司總部
    110 East 59th Street, FL 33
    公司網址
    https://www.royaltypharma.com
    公司電郵
    ir@royaltypharma.com
    公司電話
    +1 212 883-0200

    「股神」旗下巴郡上季加注能源股 包括西方石油及雪佛龍

    古美儀·
    「股神」旗下巴郡上季加注能源股 包括西方石油及雪佛龍

    美股異動 | Royalty Pharma漲4% 獲摩通上調評級

    格隆匯·
    美股異動 | Royalty Pharma漲4% 獲摩通上調評級

    美股異動 | Royalty Pharma漲4% 獲摩通上調評級

    格隆匯·
    美股異動 | Royalty Pharma漲4% 獲摩通上調評級

    關於

    Royalty Pharma plc(RPRX.US)所屬的行業板塊為Biotechnology。
    Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
    截至16/08 12:00:00,Royalty Pharma plc的股價升1.14,市值19,475.72百萬。Royalty Pharma plc的市盈率及息率分別為42.710及1.64%。
    詳細公司背景可參考: https://www.royaltypharma.com